Funds
Oncode Oncology Bridge Fund I
Oncode Oncology Bridge Fund I was established at the inception of Oncode Institute in 2019. The investment strategy included therapeutics, diagnostics and enabling technology companies in the field of oncology spun out of Oncode Institute. Ligase BioPartners took over management of this fund in 2026.
For enquiries, please use the contact page.
Portfolio companies
Innovating high-resolution single-cell discovery tools to support breakthrough research and development of precision oncology and novel biological insights.
Targeting novel biology in oncology with a focus on translating academic discovery into first-in-class small molecule therapeutics.
Developing next-generation immuno-oncology and targeted degradation approaches with the potential to overcome resistance and broaden patient benefit.
Enabling high-resolution single-cell analysis to support discovery and development of precision oncology therapeutics.
Focused on developing differentiated therapies aimed at hard-to-treat solid tumors.
Engineering cell therapies designed to modulate the tumor microenvironment and enhance durable responses.
Developing ultrasensitive liquid biopsy solutions for the detection and monitoring of cancer through circulating tumor DNA.
Therapeutic programs aimed at addressing key drivers of tumor progression and resistance.
Building a pipeline of precision therapies based on deep insights into cancer genetics and biology.
Developing immuno-oncology therapies designed to modulate immune responses and enhance anti-tumor activity.
Pursuing innovative therapeutic approaches to deliver meaningful benefit in difficult-to-treat cancers.
Early-stage stealth oncology company advancing a novel approach to treating cancer. Further details to be disclosed at a later stage.
Oncode Oncology Bridge Fund II
The fund was established in 2026 in collaboration with Oncode Institute. The investment strategy includes therapeutics and diagnostics companies addressing clinical unmet need in oncology and other associated areas. The fund is seeking investment opportunities at pre-seed and seed stage in Europe.
Share an opportunity
Key documents for investors
The information on this website is provided for informational purposes only and does not constitute investment advice, an offer, or a solicitation to invest in any fund or product.